The Latest Cardiac and Vascular News
SALT LAKE CITY, Feb. 05, 2025 (GLOBE NEWSWIRE) — Recursion (Nasdaq: RXRX) reported 12 month data from the Phase 2 study (SYCAMORE) of REC-994, the first industry sponsored Phase 2 trial completed in Cerebral Cavernous Malformations (CCM). The Company announced in September 2024 that the signal-finding study met its primary endpoint.
SAN MATEO, Calif.–(BUSINESS WIRE)–The numbers speak for themselves, RapidAI’s deep clinical AI is delivering results where competitors are falling short. New data from the largest head-to-head study to date proves RapidAI’s LVO detection outperforms Viz.ai by a staggering 33%, detecting far more stroke cases and reducing the risk of missed […]
Lowering of infarct growth – brain tissue loss – by 50% in patients treated in less than 12 hours following last known well Lowering of infarct growth correlated with clinically meaningful improvements in several functional stroke measures that evaluate a patient’s recovery TACOMA, Wash.,…
Dr. Ronald Benitez to present Vivistim safety and outcomes data for the largest cohort of ischemic stroke survivors AUSTIN, Texas and LOS ANGELES, Feb. 5, 2025 /PRNewswire/ — Dr. Ronald P. Benitez, a neurosurgeon at Atlantic Brain and Spine, will present safety and outcomes data from the…
Terumo Neuro Also Features Much-Anticipated SOFIA™ 88 Neurovascular Support Catheter Showcased at ISC Symposium led by Dr. Ameer E. Hassan on Thursday, February 6th ALISO VIEJO, Calif. and LOS ANGELES, Feb. 5, 2025 /PRNewswire/ — Terumo Neuro, a global neurovascular company and wholly…
VANCOUVER, British Columbia, Feb. 05, 2025 (GLOBE NEWSWIRE) — Algernon Pharmaceuticals Inc. (the “Company” or “AGN Pharma”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage pharmaceutical development company, is pleased to announce that its wholly owned subsidiary, Algernon NeuroScience (AGN Neuro), has appointed Validcare as the contract research organization (“CRO”) for the Company’s upcoming randomized, double-blind, placebo-controlled Phase 2a DMT study of 40 stroke patients in Europe. The study is expected to begin enrolling patients in Q3 of 2025. Validcare is a leading U.S. based full service CRO with experience across a wide range of therapeutic indications.
• This latest research builds upon the growing body of evidence demonstrating the unique impact of Brainomix’s AI-powered software to expand access to life-changing stroke treatments across networks OXFORD, England and CHICAGO, Feb. 4, 2025 /PRNewswire/ — Brainomix, an award-winning…
SAN MATEO, Calif.–(BUSINESS WIRE)–RapidAI, the global leader in AI-driven medical imaging analysis and coordinated care, has received FDA 510(k) clearance for Lumina 3D™ by RapidAI—an industry-first, automated 3D imaging reconstruction solution designed to replace manual workflows with an AI-powered approach based on the latest groundbreaking AI technology advances. “Obtaining high-quality […]
SAN FRANCISCO–(BUSINESS WIRE)–Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced an expanded partnership with Softek Illuminate, Inc., an industry leader in the development of proprietary natural language processing (NLP) and AI software that discovers at-risk patients from electronic medical records (EMR), assesses disease severity, and […]
January 29, 2025 11:05 AM Eastern Standard Time SOUTHLAKE, Texas–(BUSINESS WIRE)–Rapid Medical™, a leading developer of active endovascular devices, announces the first patient enrolled in its COGNITIVE Study–the first to examine a link between mechanical thrombectomy and cognitive improvement. TIGERTRIEVER, the only active stent retriever, may uniquely preserve cognitive function with […]
